<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02295046</url>
  </required_header>
  <id_info>
    <org_study_id>AMAT-BESD-03-RDL/10</org_study_id>
    <nct_id>NCT02295046</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10/80 mg Under Fasting Condition</brief_title>
  <official_title>Open Label, Randomized, Two-treatment, Two-period, Two-sequence,Crossover, Single Dose, Oral Bioequivalence Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10mg/80mg Under Fasting Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the bioequivalence between Amlodipine besylate/Atorvastatin calcium
      Tablets 10mg/80mg of Dr. Reddy's Laboratories Limited, India and CADUET® (amlodipine besylate
      and atorvastatin calcium) tablets 10mg/80mg of Pfizer Ireland Pharmaceuticals Dublin, Ireland
      in Healthy Male and Female Volunteers under Fasting conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, randomized, two-treatment, two-period, two-sequence, crossover, single dose, oral
      bioequivalence study of Amlodipine besylate/Atorvastatin calcium Tablets 10mg/80mg under
      Fasting conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve (AUC)</measure>
    <time_frame>0.50; 1.00; 2.00; 3.00; 4.00; 5.00; 6.00; 7.00; 8.00; 10.00; 11.00; 12.00 16.00; 24.00; 36.00;48.00 and 72.00 hours post dose for Amlodipine</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under curve (AUC)</measure>
    <time_frame>10 min; 20 min; 30 min; 40 min; 50 min; 1.00; 1.25; 1.50; 1.75; 2.00; 2.25; 2.50; 2.75; 3.00; 3.50; 4.00; 4.50; 5.00; 6.00; 8.00; 10.00; 12.00 16.00;24.00; 36.00; 48.00 and 72.00 hours post dose for Atorvastatin</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg of Dr. Reddys Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caduet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Caduet® 10/80 mg tablets of Pfizer, Ireland</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine besylate/Atorvastatin calcium</intervention_name>
    <description>Amlodipine besylate/Atorvastatin calcium 10/80 mg</description>
    <arm_group_label>Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg</arm_group_label>
    <arm_group_label>Caduet</arm_group_label>
    <other_name>Caduet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male and female volunteers between 18 and 55 years of age

          2. Subject with the Body Mass Index within 18.5 and 24.9 kg/m2, weight not less than 50
             kg

          3. Normal health as determined by personal medical history, haematology, clinical
             chemistry and urinalysis laboratory profiles

          4. Non smokers or ex-smokers that gave up smoking for at least two years prior to the
             study

          5. The subject agrees to abstain from alcohol, food and drinks containing methylxanthines
             (tea, cola, chocolate) for 48 hours prior to study drug administration and during each
             study period and from grapefruit-containing food and beverages for 48 hours prior to
             study drug administration and during each study period

          6. Ability to understand the full nature and purpose of the study, including possible
             risks and side effects; ability to cooperate with the Clinical Investigator and to
             comply with the requirements of the entire study

          7. Informed written consent given voluntary before the initiation of the pre-study
             screening

          8. Negative results to the HIV, hepatitis C or hepatitis B test

          9. Negative results from pregnancy tests (for female subjects only)

         10. Non-lactating woman (for female subjects only)

         11. Subjects using non-hormonal contraceptive measures during the study (for female
             subjects only)

         12. Normal creatine phosphokinase (CPK) levels at the time of check-in of each period.

        Exclusion Criteria:

          1. History of hypersensitivity to the test drug (Amlodipine Besylate/Atorvastatin
             Calcium) or to drugs belonging to the same pharmacological and chemical class and
             inactive ingredients of the formulation

          2. Participation in a clinical study with an investigational product in the preceding
             three months or in a clinical study with a generic product in the preceding two months

          3. Hospitalization for any reason within eight weeks prior to the study initiation

          4. Donation of 450 ml or more of blood, within eight weeks prior to the study initiation

          5. Intake of any prescription or non-prescription drug (including anti-acids, analgesics,
             statins, cyclosporin, fibric acid derivatives, erythromycin, azole antifungals,
             niacin, oral contraceptives etc.) during the two weeks preceding the study or
             throughout the study

          6. History of presence of any relevant medical condition including cancer, significant
             disease of the renal, hepatic, immunological, dermatological, gastrointestinal,
             respiratory, cardiovascular, endocrine or locomotor systems, and any metabolic,
             haematological neurological disorder or psychiatric disorder

          7. History or presence of drug or alcohol abuse, within the past year

          8. History or any current condition or other disease known to interfere with the
             absorption, distribution, metabolism or excretion of investigational medicines

          9. ECG having evidence of clinically significant abnormalities

         10. Presence of any acute or chronic infectious disease

         11. Positive results to the HIV, hepatitis C or hepatitis B tests

         12. Positive results to the breath alcohol test and drugs of abuse checks

         13. Positive results to the pregnancy tests (for female subjects only)

         14. Subject is vegetarian or follows particular diets

         15. A history of difficulty with donating blood.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. V Parasca, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>3S-Pharmacological Consultation &amp; Research GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>3S-Pharmacological Consultation &amp; Research GmbH</name>
      <address>
        <city>D-27243 Harpstedt</city>
        <state>Koenigsberger</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2014</study_first_submitted>
  <study_first_submitted_qc>November 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2014</study_first_posted>
  <last_update_submitted>November 17, 2014</last_update_submitted>
  <last_update_submitted_qc>November 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Amlodipine, atorvastatin drug combination</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

